Why blind doctorscarersevaluators

Knowledge of treatment allocation

♦ may affect the way patients are monitored, for example for side effects or disease progression, possibly leading to earlier diagnosis of failure and initiation of alternative therapy in one treatment group than the other;

♦ may affect level of reporting of adverse effects, for example over-reporting of effects in patients undergoing a relatively new treatment, while the same events might not be reported in someone undergoing standard care;

♦ may affect the patient's response, if the doctor has different levels of 'enthusiasm' for the different treatments;

♦ may affect the evaluators - for example those measuring tumour volumes to assess treatment response may be subtly influenced by knowledge of treatment allocation, perhaps giving the 'benefit of doubt' more readily to one group than the other.

0 0

Post a comment